Skip to main content

Table 4 Selected published results of SRS (2000–2015) for the treatment of prolactin-secreting pituitary adenomas

From: Target delineation and optimal radiosurgical dose for pituitary tumors

Authors

Patients

Type

dose

Follow-up

Tumor

Biochemical

Late toxicity (%)

of SRS

(Gy)

(months)

control (%)

remission (%)

visual

hypopituitarism

Landolt 2000 [124]

20

GK

29

25

85

25

0

NA

Pan L et al., 2000 [125]

128

GK

33

41

99

41

0

NA

Izawa et al., 2000 [85]

15

GK

23.6

16

100

16

0

NA

Feigl et al., 2002 [32]

18

GK

15a

55

94

60

NA

40

Choi et al., 2003 [126]

21

GK

28.5a

42.5

96.9

23.8

0

0

Petrovich et al., 2003 [60]

12

GK

15a

41

83

83

0

4

Pouratian et al., 2006 [127]

23

GK

18.6a

55

89

26

7

28

Voges et al., 2006 [66]

13

LINAC

20

56

100

15.4

4.2

18.3

Pollock et al., 2008 [118]

11

GK

18a

48

100

18 at 4 years

9.1

36

Castinetti et al., 2009 [100]

15

GK

28a

96

100

46.6

0

21

Jezkova et al., 2009 [128]

35

GK

34a

75.5

97

37.1

0

14.3

Wan et al., 2009 [98]

176

GK

22.4a

67.5

90.3

23.3

0

1.8

Tanaka et al., 2010 [129]

22

GK

25a

60

100

18

4

42 at 4 years

Sheehan et al., 2011 [36]

32

GK

24a

31

93

26

2.4

24.4

Liu et al., 2013 [130]

22

GK

15a

36

86

27.3

0

4.5

Wattson et al., 2014 [109]

9

Protons

20

60

98

22

0

57

Cohen-Inbar et al., 2015 [131]

38

GK

25a

42.3

92

50

4.2

30.3

  1. SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
  2. amarginal dose